ArrowMark Colorado Holdings LLC Has $115.09 Million Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

ArrowMark Colorado Holdings LLC decreased its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 3.8% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,010,655 shares of the biopharmaceutical company’s stock after selling 80,046 shares during the quarter. Halozyme Therapeutics makes up approximately 1.5% of ArrowMark Colorado Holdings LLC’s portfolio, making the stock its 17th largest holding. ArrowMark Colorado Holdings LLC owned 1.58% of Halozyme Therapeutics worth $115,090,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the company. GAMMA Investing LLC boosted its holdings in Halozyme Therapeutics by 96.6% during the second quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 254 shares during the period. International Assets Investment Management LLC acquired a new position in shares of Halozyme Therapeutics during the second quarter worth approximately $33,000. Skandinaviska Enskilda Banken AB publ acquired a new stake in shares of Halozyme Therapeutics in the second quarter worth $49,000. Toth Financial Advisory Corp acquired a new position in Halozyme Therapeutics during the 3rd quarter valued at $57,000. Finally, FSC Wealth Advisors LLC acquired a new stake in Halozyme Therapeutics in the 3rd quarter worth $65,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Price Performance

Shares of HALO stock opened at $48.20 on Monday. The firm has a market cap of $6.13 billion, a price-to-earnings ratio of 15.96, a PEG ratio of 0.44 and a beta of 1.29. Halozyme Therapeutics, Inc. has a 12 month low of $33.15 and a 12 month high of $65.53. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. The stock has a 50-day moving average price of $53.28 and a 200 day moving average price of $53.79.

Insider Transactions at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of the company’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $59.09, for a total transaction of $590,900.00. Following the completion of the sale, the chief executive officer now owns 676,744 shares in the company, valued at approximately $39,988,802.96. The trade was a 1.46 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders sold a total of 60,000 shares of company stock worth $3,425,000 in the last quarter. 2.40% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on HALO. Morgan Stanley boosted their price objective on Halozyme Therapeutics from $59.00 to $64.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. JMP Securities upped their price objective on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research note on Friday, November 1st. Benchmark reiterated a “buy” rating and set a $60.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, August 8th. HC Wainwright reaffirmed a “buy” rating and set a $68.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday, November 20th. Finally, Piper Sandler raised their price target on Halozyme Therapeutics from $51.00 to $52.00 and gave the company a “neutral” rating in a report on Monday, November 4th. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $61.11.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.